Imaging solid tumors using a new tracer called 68Ga-FAPI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the diagnostic accuracy of PET/CT imaging using a novel radiotracer, 68Ga-FAPI, for detecting cancers of the pancreas, stomach, bile ducts, and epithelial ovarian cancer. The approach focuses on the unique properties of cancer-associated fibroblasts (CAFs) within the tumor stroma, which are abundant in these types of cancers. By selectively targeting the Fibroblast Activation Protein (FAP), the study aims to improve the differentiation of malignant lesions from benign conditions, potentially leading to better treatment decisions. Patients scheduled for surgical removal of these tumors will be enrolled to assess the effectiveness of this imaging technique.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Consecutive patients scheduled for surgical removal of either a pancreatic, biliary or gastric lesion.

  \- Consecutive patients scheduled for primary surgical removal of early stage epithelial ovarian cancer (EOC), interval debulking surgery of EOC or surgical removal or tissue biopsy of recurrent EOC
* Signed informed consent.

Common Exclusion Criteria for all study populations:

* Age ≤18 year
* Pregnancy and lactation
* Significantly reduced renal function
* Allergy to iodinated contrast media
* Subjects that for some reason are unable to exercise their own rights, such as cognitive function impairment.

Additional Exclusion Criteria for study populations with either pancreatic-, gastric or bile duct cancer:

• Known metastatic disease

Where it's running

• Karolinska University Hospital Huddinge
  Stockholm, Sweden Recruiting

Study contacts

• Principal investigator: Rimma Axelsson, Professor — Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital
• Study coordinator: Rimma Axelsson, Professor
• Email: rimma.axelsson@ki.se
• Phone: +46 708 227 622

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Anti-mesothelin TNhYP218 CAR T cell therapy for mesothelin-expressing solid tumors

  This treatment will test whether a person's own engineered CAR T cells that target mesothelin can help adults with mesothelin-expressing solid tumors, including mesothelioma, that have returned or spread after standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06885697

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

• Pooling clinical experiences of patients treated with Lutetium-177 in Spain

  This study looks at how well Lutetium-177 works and how safe it is for patients with certain types of tumors in Spain by collecting information from their medical records.

  Recruiting at 11 sites Sociedad Española de Medicina Nuclear e Imagen Molecular · Santiago de Compostela, A Coruña and 19 other locations · NCT04949282

• Collecting samples and studying the natural history of malignant mesothelioma

  This study is collecting tissue samples from people with malignant mesothelioma and certain other cancers to learn more about the disease and help improve future treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01950572

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.